Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- [Data] Sales of Nippon Chemiphar's Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Wakamoto's Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Torii’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- Regulatory Challenges Remain for Introduction of Combination Vaccines: MSD VP Shirasawa
December 12, 2012
- Fycompa Approved for Use under NHS Scotland: Eisai
December 12, 2012
- Santen to Set Up Demand-Chain Strategic Planning Office
December 12, 2012
- Astellas, UMN Complete Administration of Seasonal Vaccine to Participants in Domestic PIII Trial
December 12, 2012
- Meta-Analysis of Study Data Finds 39% Overall Response Rate with Velcade Retreatment: Takeda
December 12, 2012
- Hisamitsu, Asahi Kasei Pharma to Comarket OAB Transdermal Drug
December 11, 2012
- Mochida Revving Up Collaboration Efforts in Biosimilars
December 11, 2012
- Otsuka Pharmaceutical Factory to Establish Infusion Products Subsidiary in India
December 11, 2012
- Ethical Drug Sales Up 6.1% in October: Crecon Report
December 11, 2012
- Feburic’s Market Share to Exceed 50% in Near Future: Teijin President Ohyagi
December 11, 2012
- Mylan Applies for Ciclosporin for Additional Indication Based on Data from Public Domain
December 11, 2012
- Teva Pharma Halts Sales of Pinatos Due to GMP Non-Compliance of South Korean Supplier
December 10, 2012
- JT Submits NDA for Anti-HIV Combination Drug, 1st NDA for Compound It Discovered
December 10, 2012
- US FDA Accepts NDA for Tacrolimus Extended-Release Capsules: Astellas
December 10, 2012
- Actavis Eyes 3 Monoclonal Antibodies for Entry into Japanese Biosimilar Market: EVP
December 10, 2012
- IP High Court Reverses JPO Ruling on Lipitor Patent
December 7, 2012
- With Spiriva Combination Product in PIII, BI Not Fear Competition in COPD Market: Chairman Barner
December 7, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…